Danish pharmaceutical company Lundbeck falls as much as 3 percent after BNP Paribas downgraded its rating to underperform from neutral ahead of Phase 3 results for the epilepsy drug bexicaserin. Bloomberg reports.
Analysts believe that a positive study result is largely already priced in after the stock’s 41 percent rise since the beginning of October.
At the same time, they point to the risk of a significant placebo effect that could make it more difficult to achieve the study’s objectives.
The bank also warns that 55–80 percent of 2026 revenue will come from products whose patent protection expires between 2030 and 2035.